Using a PHD inhibitor, Roxadustat, in these patients allow HIFs to accumulate and, thus, enhance EPO secretion and normalize Iron homeostasis, breaking the vicious cycle of anemia that affects other CV organs and increase the morbidity and mortality rate in such patients (273, 274). Here, EPO is linked to anemia (phenotype).